Data from completed Phase 1b study of ELA026 highlights results in patients with the poorest prognosis, those with malignancy-associated HLH SOUTH SAN FRANCISCO, CA, November 5, 2024 – Electra Therapeutics, Inc., a clinical stage biotechnology company developing antibody therapies against novel targets for immunological diseases and cancer, announced today that clinical data for its lead...

ELA026 has the potential to address a high unmet need for patients with a rare, life-threatening hyperinflammatory disease SOUTH SAN FRANCISCO, CA, November 4, 2024 – Electra Therapeutics, Inc., a clinical stage biotechnology company developing antibody therapies against novel targets for immunological diseases and cancer, today announced that the U.S. Food and Drug Administration (FDA)...

ELA026 has the potential to address a high unmet need for patients with a rare, life-threatening hyperinflammatory disease SOUTH SAN FRANCISCO, CA, October 30, 2024 – Electra Therapeutics, Inc., a clinical stage biotechnology company developing antibody therapies against novel targets for immunological diseases and cancer, today announced that the U.S. Food and Drug Administration (FDA)...

Data from the Phase 1b Study of ELA026 in secondary hemophagocytic lymphohistiocytosis (sHLH) highlights preliminary efficacy in patients with the poorest prognosis, those with malignancy-associated HLH  SOUTH SAN FRANCISCO, CA, October 29, 2024 – Electra Therapeutics, Inc., a clinical stage biotechnology company developing antibody therapies against novel targets for immunological diseases and cancer, announced today...

ELA026 demonstrated a high overall response rate (ORR) across a range of sHLH patients and a favorable safety profile in this life-threatening hyperinflammatory condition In patients with the poorest prognosis, those with malignancy-associated HLH, early treatment with ELA026 resulted in 100% ORR and improved survival SOUTH SAN FRANCISCO, CA, June 16, 2024 – Electra Therapeutics,...

Data from Phase 1b study of ELA026 in secondary hemophagocytic lymphohistiocytosis (sHLH) to be presented on Sunday, June 16, 2024 SOUTH SAN FRANCISCO, CA, June 3, 2024 – Electra Therapeutics, Inc., a clinical stage biotechnology company developing antibody therapies against novel targets for a broad range of immunological diseases and cancer, announced today that clinical...

SOUTH SAN FRANCISCO, CA, June 3, 2024 – Electra Therapeutics, Inc., a clinical stage biotechnology company developing antibody therapies against novel targets for a broad range of immunological diseases and cancer, announced today the appointment of Graham Parry, PhD, as Chief Scientific Officer and Kim-Hien Dao, DO, PhD, as Chief Medical Officer. Both executives have deep...

ELA026 showed favorable safety and achieved overall response rate (ORR) of 70% in sHLH patients Majority of enrolled patients were in difficult-to-treat subtypes of sHLH associated with malignancies and relapsed/refractory disease SOUTH SAN FRANCISCO, CA, December 11, 2023 – Electra Therapeutics, Inc., a clinical stage biotechnology company developing antibody therapies against novel targets for immunological diseases...

Company expands board of directors and appoints Matthew Fust as independent director Building on positive clinical results for its lead antibody candidate, Electra is positioned to expand therapeutic opportunities in immunological diseases and cancer SOUTH SAN FRANCISCO, CA, December 11, 2023 – Electra Therapeutics, a clinical stage biotechnology company developing antibody therapies against novel targets...

Company to reveal first clinical data from Phase 1b study of ELA026, its lead product candidate for life-threatening inflammatory disease, secondary hemophagocytic lymphohistiocytosis (sHLH) SOUTH SAN FRANCISCO, CA, November 2, 2023 – Electra Therapeutics, Inc., a clinical stage biotechnology company developing antibody therapies against novel targets, announced today that the company will present the initial...